Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: A contemporary analysis of 495 consecutive percutaneous coronary interventions

Journal of Invasive Cardiology

Volumn 16, Issue 11, 2004, Pages 611-616

  Deliargyris, Efthymios N ^a   Upadhya, Bharathi ^a   Applegate, Robert J ^a   Kutcher, Michael A ^a   Gandhi, Sanjay K ^a   Sane, David C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Bleeding; Glycoprotein IIb IIIa inhibitors; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; HEPARIN; HIRULOG; TIROFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEART DISEASE; HEART INFARCTION; HEART REINFARCTION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; ISCHEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; REVASCULARIZATION; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION; STROKE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COHORT STUDIES; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTRAOPERATIVE COMPLICATIONS; LENGTH OF STAY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 8844238345     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb-IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;30:956-961.
2. The EPILOG Investigators. Platelet glycoprotein IIb-IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
3. The EPISTENT Investigators. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein -IIb/IIIa blockade. Lancet 1998;352:87-92.
4. The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422-1428.
5. The RESTORE Investigators. Effect of platelet glycoprotein-IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.
6. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stem implantation (ESPRIT): A randomized, placebo-controlled trial. Lancet 2000;356:2037-2044.
7. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002;113:1-6.
8. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 1999;100:2477-2484.
9. Kini AS, Reich D, Mitre CA, et al. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria. Am J Cardiol 2001;88:1287-1290.
10. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
11. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. J Am Med Assoc 2000; 284:835-842.
12. Kimmelstiel C, Phang R, Rehman A, et al. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention. J Thromb Thrombolysis 2001;11:203-209.
13. The PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention. The Prairie Reopro versus Integrilin Cost Evaluation (PRICE) Trial. Am Heart J 2001;141:402-409.
14. Schweiger MJ, Changezi HU, Naglieri-Prescod D, et al. Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. Clin Ther 2003;25:225-34.
15. Suleiman M, Gruberg L, Hammerman H, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: Outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J Invas Cardiol 2003;15:319-323.
16. Tam SH, Sassoli PM, Jordan RE, et al. Abciximab (ReoPro, Chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998;98:1085-1091.
17. Gilchrist IC, O'Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001;104:406-411.
18. Kereiakes DJ, Broderick TM, Roth EM, et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999;84:391-395.
19. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous intervention; Results of the GOLD (AU- Assessing Ultegra) multicenter study. Circulation 2001;103:2572-2578.
20. Silletti S, Kessler T, Goldberg J, et al. Disruption of matrix metalloproteinase-2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 2001;98:119-124.
21. Coleman KR, Braden GA, Willingham MC, et al. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ Res 1999;84:1268-1276.
22. Ribeiro SM, Schultz-Cherry S, Murphy-Ullrich JE. Heparin-binding vitronectin up-regulates latent TGF-beta production by bovine aortic endothelial cells. J Cell Sci 1995;108:1553-1561.
23. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996;98:863-874.
24. Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528-535.
25. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-167.
26. Mickelson JK, Ali MN, Kleiman NS, et al. Chimeric 7E3 Fab (Reopro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 1999;33:97-106.
27. Aggarwal A, Schneider DJ, Terrien EF, et al. Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardiol 2003;91:1346-1349.
28. Welt FGP, Rogers SD, Zhang X et al. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Cathet Cardiovasc Interv 2004;61:185-189.
29. Dalby M, Montalescot G, dit Sollier CB, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. J Am Coll Cardiol 2004;43:162-168.
30. Merino A, Segura I, Vidal B, et al. Eptifibatide blocks C-reactive protein increases after coronary angioplasty. J Am Coll Cardiol 2003;41:233A.
31. Marciniak SJ Jr, Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: Dispersal of newly formed platelet aggregates. Thromb Haemost 2002;87:1020-1025.
32. Biondi-Zoccai GGL, Abbate A, Liuzzo G, et al. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003;41:1071-1077.
33. Buffon A, Biasucci LM, Liuzzo G, et al. Wide spread coronary inflammation, in unstable angina. N Engl J Med 2002;347:5-12.
34. Deliargyris EN, Raymond RJ, Theoharides TC, et al. Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. Am J Cardiol 2000;86:913-918.
35. Steinhubl SR, Berger PB, Mann JT III, et al. CREDO Investigators. Clopidogrel for the Reduction of Events during Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. J Am Med Assoc 2002;288:2411-2420.